Global Blood Therapeutics Announces Upcoming Investor Webcast To Review GBT440 Data Being Presented At American Society of Hematology That Support Sickle Cell Disease Program
Published: Dec 01, 2016
SOUTH SAN FRANCISCO, Calif., Nov. 30, 2016 (GLOBE NEWSWIRE) -- Global Blood Therapeutics, Inc. (GBT) (NASDAQ:GBT), today announced that it will host an investor webcast on Monday, December 5, 2016, at 12:15 p.m. PT/3:15 p.m. ET, to review new data being presented at the 58th American Society of Hematology (ASH) Annual Meeting & Exposition Conference in San Diego that support its GBT440 program in sickle cell disease (SCD). The investor event will feature members of GBT’s management team and SCD experts Dr. Jo Howard of Guy’s and St. Thomas’ NHS Foundation Trust, London, UK, Dr. Wally R. Smith of Virginia Commonwealth University, and Dr. Jeremy Hobart of Peninsula Schools of Medicine and Dentistry.
The event will highlight data presented at the ASH meeting from GBT’s ongoing Phase 1/2 GBT440-001 trial including results of dosing GBT440 at 900 mg per day in SCD patients for up to 6 months, and the metabolism of GBT440 in healthy subjects, as well as the methodology utilized to develop the Patient Reported Outcome (PRO) tool that will be used in the Company’s planned Phase 3 clinical trial of GBT440 in SCD patients, titled the HOPE (Hemoglobin Oxygen Affinity Modulation to Inhibit HbS PolymErization) Study.
The investor event will be webcast live and available for replay from GBT's website at www.globalbloodtx.com in the Investors & Media section.
About Global Blood Therapeutics
Global Blood Therapeutics, Inc. is a clinical-stage biopharmaceutical company dedicated to discovering, developing and commercializing novel therapeutics to treat grievous blood-based disorders with significant unmet need. GBT is developing its lead product candidate, GBT440, as an oral, once-daily therapy for sickle cell disease and expects to initiate its Phase 3 clinical trial by the end of 2016. GBT is also investigating GBT440 for the treatment of hypoxemic pulmonary disorders in two ongoing Phase 2a studies in patients with idiopathic pulmonary fibrosis. To learn more, please visit: www.globalbloodtx.com.
Statements we make in this press release may include statements that are not historical facts and are considered forward-looking within the meaning of Section 27A of the Securities Act of 1933, as amended and Section 21E of the Securities Exchange Act of 1934, as amended. We intend these forward-looking statements, including statements regarding the therapeutic potential and safety profile of GBT440, our ability to implement our clinical development plans for GBT440, the timing of, and our ability to generate data from, our ongoing Phase 1/2 clinical trial of GBT440 and our ability to enroll patients in and begin screening in our HOPE Study, to be covered by the safe harbor provisions for forward-looking statements contained in Section 27A of the Securities Act and Section 21E of the Securities Exchange Act and are making this statement for purposes of complying with those safe harbor provisions. These forward-looking statements reflect our current views about our plans, intentions, expectations, strategies and prospects, which are based on the information currently available to us and on assumptions we have made. We can give no assurance that the plans, intentions, expectations or strategies will be attained or achieved, and furthermore, actual results may differ materially from those described in the forward-looking statements and will be affected by a variety of risks and factors that are beyond our control including, without limitation, the risks that our clinical and preclinical development activities may be delayed or terminated for a variety of reasons, that regulatory authorities may disagree with our clinical development plans or require additional studies or data to support further clinical investigation of our product candidates, and that drug-related adverse events may be observed in later stages of clinical development, along with those risks set forth in our Annual Report on Form 10-K for the fiscal year ended December 31, 2015, and in our Quarterly Reports on Form 10-Q for the quarters ended March 31, 2016, June 30, 2016 and September 30, 2016, as well as discussions of potential risks, uncertainties and other important factors in our subsequent filings with the U.S. Securities and Exchange Commission. Except as required by law, we assume no obligation to update publicly any forward-looking statements, whether as a result of new information, future events or otherwise.
Contact Information: Myesha Lacy (investors) Global Blood Therapeutics 650-351-4730 firstname.lastname@example.org Julie Normart (media) BrewLife 415-946-1087 email@example.com